Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 68

1.

The spectrum of clinical trials aiming at personalizing medicine.

Tourneau CL, Kamal M, Alt M, Verlingue L, Servois V, Sablin MP, Servant N, Paoletti X.

Chin Clin Oncol. 2014 Jun;3(2):13. doi: 10.3978/j.issn.2304-3865.2014.05.02.

2.

Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.

Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T.

Biom J. 2015 Feb 12. doi: 10.1002/bimj.201400049. [Epub ahead of print]

PMID:
25682941
3.

[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB].

Ezzalfani M, Dugué A, Mollevi C, Pulido M, Bonnetain F, Filleron T, Gal J, Gauthier M, Le Deley MC, Le Tourneau C, Médioni J, Nguyen JM, Chabaud S, Teixeira L, Thivat E, You B, Kramar A, Paoletti X.

Bull Cancer. 2015 Jan;102(1):73-82. doi: 10.1016/j.bulcan.2014.10.001. Epub 2015 Jan 2. Review. French.

PMID:
25609488
4.

Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.

Diouf M, Bonnetain F, Barbare JC, Bouché O, Dahan L, Paoletti X, Filleron T.

Oncologist. 2015 Jan;20(1):62-71. doi: 10.1634/theoncologist.2014-0175. Epub 2014 Dec 26.

PMID:
25542450
5.

Designs of drug-combination phase I trials in oncology: a systematic review of the literature.

Riviere MK, Le Tourneau C, Paoletti X, Dubois F, Zohar S.

Ann Oncol. 2015 Apr;26(4):669-674. Epub 2014 Nov 17. Review.

PMID:
25403591
6.

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials.

Doussau A, Thiébaut R, Geoerger B, Schöffski P, Floquet A, Le Deley MC, Mathoulin-Pélissier S, Rizzo E, Fumoleau P, Le Tourneau C, Paoletti X.

Ann Oncol. 2015 Feb;26(2):422-8. doi: 10.1093/annonc/mdu523. Epub 2014 Nov 17.

PMID:
25403589
7.

Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts.

de Plater L, Vincent-Salomon A, Berger F, Nicolas A, Vacher S, Gravier E, Thuleau A, Karboul N, Richardson M, Elbaz C, Marangoni E, Bièche I, Paoletti X, Roman-Roman S, Culp PA, Asselain B, Diéras V, Decaudin D.

PLoS One. 2014 Nov 6;9(11):e104227. doi: 10.1371/journal.pone.0104227. eCollection 2014.

8.

Long-term follow-up of TaG1 non-muscle-invasive bladder cancer.

Olivier Bosset P, Neuzillet Y, Paoletti X, Molinie V, Botto H, Lebret T.

Urol Oncol. 2015 Jan;33(1):20.e1-7. doi: 10.1016/j.urolonc.2014.09.001. Epub 2014 Oct 2.

PMID:
25282704
9.

REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours.

Lévy C, Allouache D, Lacroix J, Dugué AE, Supiot S, Campone M, Mahe M, Kichou S, Leheurteur M, Hanzen C, Dieras V, Kirova Y, Campana F, Le Rhun E, Gras L, Bachelot T, Sunyach MP, Hrab I, Geffrelot J, Gunzer K, Constans JM, Grellard JM, Clarisse B, Paoletti X.

Ann Oncol. 2014 Dec;25(12):2351-6. doi: 10.1093/annonc/mdu465. Epub 2014 Oct 1.

PMID:
25274615
10.

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.

Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C, Chapeaublanc E, Hérault A, Kamoun A, Caillault A, Letouzé E, Elarouci N, Neuzillet Y, Denoux Y, Molinié V, Vordos D, Laplanche A, Maillé P, Soyeux P, Ofualuka K, Reyal F, Biton A, Sibony M, Paoletti X, Southgate J, Benhamou S, Lebret T, Allory Y, Radvanyi F.

Sci Transl Med. 2014 Jul 9;6(244):244ra91. doi: 10.1126/scitranslmed.3008970.

PMID:
25009231
11.

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Paoletti X, Le Tourneau C, Verweij J, Siu LL, Seymour L, Postel-Vinay S, Collette L, Rizzo E, Ivy P, Olmos D, Massard C, Lacombe D, Kaye SB, Soria JC.

Eur J Cancer. 2014 Aug;50(12):2050-6. doi: 10.1016/j.ejca.2014.04.030. Epub 2014 Jun 10.

PMID:
24928189
12.

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.

Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, Fowst C, Levy B, Mancini P, Lacombe D, Ivy P, Seymour L, Le Tourneau C, Siu LL, Kaye SB, Verweij J, Soria JC.

Eur J Cancer. 2014 Aug;50(12):2040-9. doi: 10.1016/j.ejca.2014.04.031. Epub 2014 May 28.

PMID:
24880774
13.

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.

Le Tourneau C, Paoletti X, Servant N, Bièche I, Gentien D, Rio Frio T, Vincent-Salomon A, Servois V, Romejon J, Mariani O, Bernard V, Huppe P, Pierron G, Mulot F, Callens C, Wong J, Mauborgne C, Rouleau E, Reyes C, Henry E, Leroy Q, Gestraud P, La Rosa P, Escalup L, Mitry E, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Gavoille C, Kamal M.

Br J Cancer. 2014 Jul 8;111(1):17-24. doi: 10.1038/bjc.2014.211. Epub 2014 Apr 24.

PMID:
24762958
14.

Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment.

Le Tourneau C, Paoletti X, Coquan E, Sablin MP, Zoubir M, Tannock IF.

J Clin Oncol. 2014 Jan 20;32(3):260-3. doi: 10.1200/JCO.2013.53.5518. Epub 2013 Dec 2. No abstract available.

15.

Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.

Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buyse M, Burzykowski T; GASTRIC group.

J Natl Cancer Inst. 2013 Nov 6;105(21):1600-7. doi: 10.1093/jnci/djt270. Epub 2013 Oct 9. Review.

16.

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

Paoletti X, Oba K, Bang YJ, Bleiberg H, Boku N, Bouché O, Catalano P, Fuse N, Michiels S, Moehler M, Morita S, Ohashi Y, Ohtsu A, Roth A, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Thuss-Patience P, Van Cutsem E, Burzykowski T, Buyse M; GASTRIC group.

J Natl Cancer Inst. 2013 Nov 6;105(21):1667-70. doi: 10.1093/jnci/djt269. Epub 2013 Oct 9.

17.

Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.

Doussau A, Thiébaut R, Paoletti X.

Stat Med. 2013 Dec 30;32(30):5430-47. doi: 10.1002/sim.5960. Epub 2013 Sep 10.

PMID:
24018535
18.

[What is the contribution of tumor response in colorectal cancer?].

Bachet JB, Paoletti X, Fournier L, Rougier P.

Bull Cancer. 2013 Jul-Aug;100(7-8):743-55. doi: 10.1684/bdc.2013.1780. Review. French.

PMID:
23831844
19.

A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.

Paoletti X, Geoerger B, Doz F, Baruchel A, Lokiec F, Le Tourneau C.

Eur J Cancer. 2013 Jul;49(10):2392-402. doi: 10.1016/j.ejca.2013.02.028. Epub 2013 Mar 27.

PMID:
23540589
20.

Dealing with missing data in the Center for Epidemiologic Studies Depression self-report scale: a study based on the French E3N cohort.

Resseguier N, Verdoux H, Giorgi R, Clavel-Chapelon F, Paoletti X.

BMC Med Res Methodol. 2013 Feb 21;13:28. doi: 10.1186/1471-2288-13-28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk